- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Pipe on Current Trends in Hemophilia Incidence
About 1 in 5000 males are born with hemophilia, according to Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program.
About 1 in 5000 males are born with hemophilia, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program
Transcript
What are some current trends in hemophilia incidence?
Hemophilia is a congenital disorder. It's a defective gene for factor VIII, which is hemophilia A or defective gene for factor VIIII, which is hemophilia B. The incidence of hemophilia A and B has been quite static for decades, and it's probably because we've improved the health of carriers as well as the population itself. So, we really don't see any significant changes going forward from what we've been used to seeing over the last few years. There's 30,000-33,000 patients with hemophilia in the US, about 85% of those have hemophilia A, so a factor VIII deficiency; the others are hemophilia B. Just to give you some perspective, it's about 1 in 5000 male births affected by hemophilia. And of those, almost 50% of them are going to have the severe form of the condition.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
